Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical neuropharmacology

• Publication date

  2008-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/WNF.0b013e3181633497PMID 18978501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

  2007cited by this paper
• Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects

  2007cited by this paper
• Cannabis use in patients with multiple sclerosis

  2006cited by this paper
• Long-term effects of frequent cannabis use on working memory and attention: an fMRI study

  2006cited by this paper
• Outcome of new benzodiazepine prescriptions to older adults in primary care.

  2006cited by this paper
• The PASAT performance among patients with multiple sclerosis: analyses of responding patterns using different scoring methods

  2006cited by this paper
• Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

  2006cited by this paper
• Neuropsychological deficits in long-term frequent cannabis users.

  2006cited by this paper
• Cannabis use and mental health in secondary school children

  2006cited by this paper
• Is Cannabis Use a Contributory Cause of Psychosis?

  2006cited by this paper
• Cannabis as a risk factor for psychosis: systematic review

  2005cited by this paper
• Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

  2005cited by this paper
• Cannabis use andmental health in secondary school children Findings from a Dutch survey

  2005cited by this paper
• Cannabinoids in multiple sclerosis: urgent need for long term trials

  2005cited by this paper
• Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

  2005cited by this paper
• Cannabis use and misuse prevalence among people with psychosis.

  2005cited by this paper
• Long-term effects of exposure to cannabis.

  2005cited by this paper
• Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

  2004cited by this paper
• Clinical Implications and Methodological Challenges in the Study of the Neuropsychological Correlates of Cannabis, Stimulant, and Opioid Abuse

  2004cited by this paper
• Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

  2004cited by this paper
• Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

  2004cited by this paper
• The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

  2004cited by this paper
• Early adolescent cannabis exposure and positive and negative dimensions of psychosis.

  2004cited by this paper
• Comorbid cannabis use and panic disorder: short term and long term follow‐up study

  2004cited by this paper
• Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life.

  2004cited by this paper
• Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples.

  2004cited by this paper
• Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

  2003cited by this paper
• Psychoactive Drugs and Quality of Life

  2003cited by this paper
• Marijuana alters the human cerebellar clock

  2003cited by this paper
• Cognitive functioning of long-term heavy cannabis users seeking treatment.

  2002cited by this paper
• Safety, tolerability, and efficacy of orally administered cannabinoids in MS

  2002cited by this paper
• Measuring fatigue in patients with Parkinson's disease – the Fatigue Severity Scale

  2002cited by this paper
• Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users

  2002cited by this paper
• Abuse, dependence, or withdrawal associated with tramadol.

  2002cited by this paper
• The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.

  2001cited by this paper
• Cannabinoids in Clinical Practice

  2000cited by this paper
• Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report.

  2000cited by this paper
• The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

  1999cited by this paper
• The perceived effects of smoked cannabis on patients with multiple sclerosis.

  1997cited by this paper
• A community survey of adverse effects of cannabis use.

  1996cited by this paper
• Benzodiazepine Dependence

  1993cited by this paper
• SCL-90-R, Administration, Scoring, and Procedures Manual-II for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• A rating instrument for anxiety disorders.

  1971cited by this paper

• Cannabidiol in Neurology: Current Insights and Translational Perspectives.

  2026cites this paper
• The Association Between Cannabis Use and Paranoia: Meta-Analysis of Experimental and Observational Studies.

  2025cites this paper
• Safety and effectiveness of Co-careldopa for motor recovery in post-stroke patients: A Systematic Review

  2025cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• Cannabiskonsum und Cannabiskonsumstörungen

  2024cites this paper
• Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation

  2024cites this paper
• Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials

  2023cites this paper
• Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder.

  2023cites this paper
• The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review

  2023influential citation
• Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies

  2023cites this paper
• Endocannabinoid System and the Otolaryngologist.

  2022cites this paper
• Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  2022cites this paper
• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

  2022cites this paper
• Effects of Sativex® on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis.

  2022cites this paper
• The effect of medical cannabis on cognitive functions: a systematic review

  2022cites this paper
• Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

  2022cites this paper
• Cannabidiol in the Treatment of Mood Disorders

  2022cites this paper
• Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

  2022cites this paper
• Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  2022cites this paper
• Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials

  2021cites this paper
• A systematic review of the effects of cannabis on cognition in people with multiple sclerosis.

  2021cites this paper
• Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

  2020cites this paper
• The pharmacological effects of inhaled cannabis on pain in patients with multiple sclerosis: risks versus rewards

  2020cites this paper
• Cannabis and Multiple Sclerosis.

  2020cites this paper
• Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.

  2020cites this paper
• Toxicological Properties of Δ9-tetrahydrocannabinol and Cannabidiol

  2020cites this paper
• The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis

  2020cites this paper
• A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment

  2020cites this paper
• The molecular mechanisms that underpin the biological benefit of full spectrum cannabis extract in the treatment of neuropathic pain and inflammation.

  2020cites this paper
• Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain

  2020cites this paper
• Cannabis-based medicines and the perioperative physician

  2019cites this paper
• Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.

  2019cites this paper
• Cannabidiol as a Treatment for Mood Disorders: A Systematic Review

  2019influential citation
• Appendix C: References (Part I)

  2018cites this paper
• The analgesic potential of cannabinoids.

  2018cites this paper
• Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

  2018cites this paper
• Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

  2018cites this paper
• Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

  2018cites this paper
• Appendix B: Quality Research, Evidence of Effectiveness of Medical Cannabis

  2018cites this paper
• Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity

  2017cites this paper
• Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review

  2017cites this paper
• Cannabinoids for the treatment of dementia.

  2017cites this paper
• A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

  2017cites this paper
• Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.

  2017cites this paper
• Are cannabinoids effective in multiple sclerosis?

  2017cites this paper
• Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis

  2016cites this paper
• Medicinal Uses of Marijuana and Cannabinoids

  2016cites this paper
• Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs.

  2016cites this paper
• Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.

  2016cites this paper
• Cognitive Issues in Multiple Sclerosis

  2016cites this paper
• Assessing the Neurophysiological Effects of Cannabinoids on Spasticity in Multiple Sclerosis

  2015cites this paper
• Therapeutic Advances in Neurological Disorders

  2015cites this paper
• Medical Marijuana: The State of the Science

  2015cites this paper
• Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity

  2015cites this paper
• What to make of cannabis and cognition in MS: In search of clarity amidst the haze

  2015cites this paper
• Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

  2015cites this paper
• Une avancée pour la prise en charge de la spasticité dans la sclérose en plaques

  2015cites this paper
• Use of Cannabinoids for Spasticity and Pain Management in MS

  2015cites this paper
• Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

  2015cites this paper
• [A breakthrough for the treatment of spasticity in multiple sclerosis].

  2015cites this paper
• Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

  2014cites this paper
• Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

  2014cites this paper
• Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

  2014cites this paper
• Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis

  2014cites this paper
• Evidence-based guideline : Complementary and alternative medicine in multiple sclerosis Report of the Guideline Development Subcommittee of the American Academy of Neurology

  2014cites this paper
• Prescrire du cannabis fumé pour la douleur chronique non cancéreuse: Recommandations préliminaires

  2014cites this paper
• A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis

  2014cites this paper
• Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.

  2014cites this paper
• Pharmacological treatment for memory disorder in multiple sclerosis.

  2013cites this paper
• Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice

  2013cites this paper
• Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report

  2013cites this paper
• Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy.

  2013cites this paper
• Role of Cannabinoids in Pain Management

  2013cites this paper
• Correlation analysis of visual analogue scale and measures of walking ability in multiple sclerosis patients

  2013cites this paper
• Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

  2012cites this paper
• Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

  2012cites this paper
• Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?

  2012cites this paper
• The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

  2012cites this paper
• Comorbid Trajectories of Tobacco and Marijuana Use as Related to Psychological Outcomes

  2012cites this paper
• Potential control of multiple sclerosis by cannabis and the endocannabinoid system.

  2012cites this paper
• [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

  2012cites this paper
• Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.

  2012cites this paper
• Treatment of cognitive impairment in patients with multiple sclerosis

  2012influential citation
• Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides

  2012cites this paper
• EFFECTS OF ACUTE AND CHRONIC TREATMENT WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND THE CANNABINOID RECEPTOR AGONIST WIN55,212-2 ON BEHAVIOUR AND COGNITION IN RATS

  2012cites this paper
• Pharmacologic treatment for memory disorder in multiple sclerosis.

  2011cites this paper
• A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

  2011cites this paper
• Medical Student Essay Competition 2011 Winning Entry

  2011cites this paper
• Empowering decision-making in cannabis use in multiple sclerosis

  2011cites this paper
• Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids*

  2011cites this paper
• THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

  2011cites this paper
• A drug discovery case history of ‘delta-9-tetrahydrocannabinol, cannabidiol’

  2011cites this paper
• Effects of cannabis on cognitive function in patients with multiple sclerosis

  2011cites this paper
• Review on clinical studies with cannabis and cannabinoids 2005-2009

  2010cites this paper
• New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

  2010cites this paper
• THEMED ISSUE: CANNABINOIDS REVIEW The endocannabinoid system as a target for the treatment of neurodegenerative disease

  2010cites this paper
• Novedades sobre el cannabis

  2009cites this paper
• Neurology Development Subcommittee of the American Academy of alternative medicine in multiple sclerosis : Report of the Guideline Summary of evidence-based guideline : Complementary and

  year unknowncites this paper